Work by Muliaditan and colleagues shed light on the potential role of HO-1 as an immune checkpoint proposing tin-mesoporphyrin (SnMP) as a novel immune checkpoint inhibitor to be used in combination with chemotherapy allowing immunological control of tumor growth in different preclinical models of BC. This evidence concerns the gene HMOX1 and breast cancer.